The Technical Analyst
Precigen Inc [PGEN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Precigen Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.76% $1.320
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 328.57 mill |
| EPS: | -0.390 |
| P/E: | -3.38 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 248.92 mill |
| Avg Daily Volume: | 1.023 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.38 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.57x |
| Company: PE -3.38 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0503 (-103.81%) $-1.370 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.222 - 1.418 ( +/- 7.42%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-05 | Thomasian Harry Jr. | Buy | 135 714 | Common Stock |
| 2024-04-05 | Thomasian Harry Jr. | Sell | 67 389 | Common Stock |
| 2024-04-05 | Thomasian Harry Jr. | Buy | 135 714 | Restricted Stock Units |
| 2024-04-05 | Thomasian Harry Jr. | Sell | 135 714 | Restricted Stock Units |
| 2024-04-05 | Perez Jeffrey Thomas | Buy | 142 857 | Common Stock |
| INSIDER POWER |
|---|
| 34.56 |
| Last 99 transactions |
| Buy: 8 317 118 | Sell: 3 939 504 |
Forecast:
16:00 - $1.330
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.330
Forecast 2: 16:00 - $1.330
Forecast 3: 16:00 - $1.330
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.320 (0.76% ) |
| Volume | 1.099 mill |
| Avg. Vol. | 1.023 mill |
| % of Avg. Vol | 107.47 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PGEN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $1.380 | N/A | Active |
|---|
PGEN
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Latest Press Releases
2024-03-28 16:05:00 - Press Release
Precigen And Recurrent Respiratory Papillomatosis Foundation To Hold Inaugural International Rrp Awareness Day On June 11th
– inaugural multi-stakeholder event on june 11th (6/11) will raise awareness and bring together individuals living with rrp, caregivers, clinicians, and government officials – – rrp is a rare, hpv-driven disease with no fda-approved therapeutic – germantown, md. , march 28, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the company has teamed up with the recurrent respiratory papillomatosis foundation (rrpf) to launch the first rrp awareness day™ on june 11, 2024, a multi-stakeholder event to raise awareness about recurrent respiratory papillomatosis (rrp) and bring together rrp patients and their caregivers to encourage new connections and build community among those interested in and affected by this devastating disease.
2024-03-19 16:05:00 - Press Release
Precigen Reports Full Year 2023 Financial Results And Business Updates
– significant progress made in the development of the prgn-2012 adenoverse immunotherapy for the treatment of rrp; precigen plans to submit a bla under an accelerated approval pathway in the second half of 2024; ramping up commercial readiness activities for a potential launch in 2025 – – precigen's prgn-2012 received the first breakthrough therapy designation and accelerated approval pathway from the fda for the treatment of rrp – – precigen received ind clearance for a randomized phase 2 study of prgn-2009 adenoverse immunotherapy in combination with pembrolizumab in hpv-associated recurrent/metastatic cervical cancer; study now active and recruiting patients – – interim data from the ongoing phase 1b study of prgn-3006 ultracar-t in relapsed/refractory aml anticipated in the second half of 2024 – – preliminary data from the phase 1 study of prgn-3007 next generation ultracar-t in ror1+ advanced cancers anticipated in the second half of 2024 – – cash, cash equivalents, short-term and long-term investments totaled $62...
2024-03-12 16:05:00 - Press Release
Precigen To Participate In A Fireside Chat Hosted By Cantor Fitzgerald To Discuss Prgn-2012 Adenoverse Immunotherapy For The Treatment Of Recurrent Respiratory Papillomatosis
Germantown, md. , march 12, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that cantor fitzgerald will be hosting a virtual fireside chat with precigen on monday, march 25, 2024 at 1:00 pm et to discuss the investigational prgn-2012 adenoverse ™ immunotherapy for the treatment of recurrent respiratory papillomatosis (rrp).
2024-03-05 16:05:00 - Press Release
Precigen To Announce Fourth Quarter And Full Year 2023 Financial Results On March 19th
Germantown, md. , march 5, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the company will report fourth quarter and full year 2023 financial results on tuesday, march 19, 2024.
2024-02-06 16:05:00 - Press Release
Precigen To Participate In The Oppenheimer 34th Annual Healthcare Life Sciences Conference
Germantown, md. , feb. 6, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced helen sabzevari, phd, president and ceo of precigen, will participate in the oppenheimer 34th annual healthcare life sciences conference taking place virtually from february 13 to february 14, 2024.
Latest News
2024-01-19 19:39:39 - Seeking Alpha
Precigen: RRP Targeting With AdenoVerse Technology Platform
FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA filing of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis is expected in the 2nd half of 2024. It is projected that it could earn $2 billion in peak sales globally of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis.
2023-12-18 16:05:00 - PRNewsWire
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GERMANTOWN, Md., Dec. 18, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 42nd Annual J.P.
2023-12-04 15:38:21 - InvestorPlace
5 ‘Jackpot' Stocks to Buy for 2024 for 10X Gains
2023-11-22 14:22:43 - InvestorPlace
3 Penny Stocks to Buy to Turn $1 into $100: November 2023
In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through penny stocks.
2023-09-05 11:17:09 - Zacks Investment Research
Should You Buy Precigen, Inc. (PGEN) After Golden Cross?
Precigen, Inc. (PGEN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, PGEN's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
2023-08-17 12:16:09 - PennyStocks
10 Top Penny Stocks To Buy According To Insiders In August
Engaging in the world of low-cost stocks often referred to as penny stocks, is appealing to those looking to capitalize on the potential upsides of the stock market. These stocks, priced below $5, are known for their intrinsic risk.
2023-08-09 15:03:06 - Seeking Alpha
Precigen, Inc. (PGEN) Q2 2023 Earnings Call Transcript
Precigen, Inc. (NASDAQ:PGEN ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Executive Officer Harry Thomasian - Chief Financial Officer Conference Call Participants Jason Butler - JMP Securities Jennifer Kim - Cantor Fitzgerald Arthur He - H.C. Wainwright Ben Burnett - Stifel Brian Cheng - JPMorgan Operator Good morning and welcome to the Precigen Second Quarter and First Half 2023 Financial Results and Business Update Call.
2023-05-19 06:40:50 - InvestorPlace
Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich
High-risk penny stocks have long tempted investors with the potential for significant returns. However, it is crucial to acknowledge the inherent risks associated with these speculative investments.
2023-05-04 13:56:05 - InvestorPlace
7 High-Potential Penny Stocks in the Biotech Sector
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.
2023-05-03 08:30:00 - PRNewsWire
Precigen to Announce First Quarter 2023 Financial Results on May 10th
GERMANTOWN, Md. , May 3, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release first quarter 2023 financial results on Wednesday, May 10, 2023.